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The young history of psychopharmacology 
began by studying the inﬂ  uence of drugs, 
whatever they were, on the behaviour of 
both rodents and human. That was the birth 
of psychotropic’s found by serendipity. After 
a few years, psychopharmacology began to 
evaluate scientiﬁ  cally the “old” drugs and 
the new one; it was the true beginning of 
a new science.
Nowadays psychopharmacology is a 
link between the neurosciences and the 
psychiatry. The emergence of precise tar-
gets of drugs in the brain with the help of 
binding studies was a great progress in the 
discovery of new drugs and the beginning 
of the knowledge of mechanisms of action. 
But the main challenge is to understand the 
correlates on the different areas of brain and 
on the entire body.
Animal models for psychopathology have 
become an invaluable tool in the analysis of 
the multitude of causes, genetic, environ-
mental or pharmacological that can bring 
about symptoms homologous to those of 
patients with a speciﬁ  c disorder (Bourin, 
1997),  despite traditional difﬁ  culties  in 
accepting these models that stem from the 
argument that there is no evidence for con-
cluding that what occurs in the brain of the 
animal is equivalent to what occurs in the 
brain of a human.
Currently animal models are sought that 
have three types of validity:
–  Face validity, where the model is phe-
notypically similar and implies that the 
response observed in the animal model 
should be identical to the behavioural 
and physiological responses observed 
in humans. The behavioural respon-
ses/repertoire of mice is of course very 
different from the human ethogram, 
which includes the verbal aspect that is 
absent in rodents.
–  Predictive validity entails that the model 
should be sensitive to clinically effective 
pharmacological agents and conversely 
anxiogenic compounds should elicit 
opposite effects, while agents that have 
no effect in the clinic should have no 
effect in these tests.
–  The criterion of construct validity rela-
tes to the similarity between the theo-
retical rationale underlying the animal 
model and the human behaviour. This 
requires that the aetiology of the beha-
viour and the biological factors under-
lying the disorder may be similar in 
animals and humans.
Often researchers fail to specify if they 
are seeking a correlation model (e.g. predic-
tive validity, a model that is selectivity sensi-
tive to therapeutic agents), an isomorphic 
model (face validity, a model that implies 
the behavioural response in the human and 
animal is the same) or a homologous model 
(true construct validity, a model that implies 
the “cause” of the behavioural response in 
the animal is sufﬁ  cient to provoke the same 
response in humans).
Behaviour can be both an event and 
a process and observable behaviours are 
the result of the integration of all of the 
processes ongoing in underlying organ 
systems, in interaction with the external 
social and physical environment. Animal 
models can allow the study of mechanisms 
of speciﬁ   c behaviours and their patho-
physiology and can aid in developing 
and predicting therapeutic responses to 
pharmacological agents.
The translation of preclinical research to 
clinical concerns is in my opinion the main 
goal of psychopharmacology. For years ani-
mal models of depression, anxiety and psy-
chosis were developed but there are mainly 
restricted to a core symptom of a psychiatric 
disorder, which is not always speciﬁ  c of the 
illness. For example, anhedonia could be 
part of depression as well as schizophrenia, 
it is the case of the chronic mild stress which 
itself is not a pure test predicting antidepres-
sant activity. In the next future preclinical 
experimental models will gain in relevance if 
they incorporate  maladaptive  physiological 
or behavioural changes that have some 
correspondence with species behavioural 
adaptations. Preclinical data are more read-
ily translated to the clinical situation when 
they are based on converging evidence from 
several experimental procedures, each cap-
turing cardinal features of the disorder. That 
is the main problem to solve the gap between 
preclinical and clinical psychopharmacology 
(Shekhar et al., 2001).
Anxiety models in rodents seems to be 
closed to human anxiety and fear, but the 
pathophysiology of anxious disorders is 
complex, it is linked to abnormal regula-
tion of several neurobiological compo-
nents including 5-HT, GABA, glutamate, 
CCK during period of stress but not typi-
cally during periods of rest. We use gener-
ally ethologically based animal models of 
fear and anxiety attempt to approximate 
the natural conditions under which such 
emotional states are elicited. By employing 
non-painful aversive stimuli to induce fear 
and anxiety, ethological tests are thought 
to minimise possible confounding effects 
of motivational or perceptual states arising 
from interference with learning/memory, 
hunger/thirst or nociceptive mechanisms 
and allow for a truly comprehensive 
“behavioural proﬁ   ling” of experimental 
interventions. When compared to condi-
tioned models, ethologically based tests 
seem to be better qualiﬁ  ed analogues of 
human anxiety. Ethological models, how-
ever, present individual differences, variable 
behavioural baseline levels (Bourin et al., 
2007). Nonetheless, ethological stimuli are 
diverse in nature. Producing conditioned 
fear in animals requires the pairing of a 
previously neutral stimulus with an elec-
tric shock, excepted for the four plates test. 
Subsequent presentations of the stimulus 
disrupt ongoing behaviour and produce 
avoidance or defence.
In conclusion, psychopharmacology 
approaches will continue by ingenious inno-
vations to make inroads in preclinical and 
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mechanism of action and the location of 
the activity (Petit-Demoulière et al., 2009) 
in both animal and human. Another chal-
lenge is the modelling of bipolar disorder in 
rodents, to improve the discovery of mood 
stabilizers.
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neurosciences and genetics. The challenge 
is to convince clinicians to study the “clini-
cal features” of rodents at least to compare 
the behaviour of both humans and animals. 
The more closely a model approximates sig-
niﬁ  cant clinical symptoms, the more able it 
is to produce data that will induce clinical 
beneﬁ  ts (Miczek and de Wit, 2008). These 
new models must be validated by predict-
ing treatments with agents having demon-
strated activity in human so that leads to 
new drugs based on the same mechanism of 
action! The challenge would be to identify 
psychological processes pertinent to affect 
and cognition, to be studied in preclinical 
models if they are deﬁ  ned in behavioural 
and neural terms. Brain imaging also must 
contribute to the knowledge of drugs’ 